Target Price | $39.78 |
Price | $35.23 |
Potential | 12.92% |
Number of Estimates | 27 |
27 Analysts have issued a price target CSX 2026 . The average CSX target price is $39.78. This is 12.92% higher than the current stock price. The highest price target is $47.25 34.12% , the lowest is $27.27 22.59% . | |
A rating was issued by 32 analysts: 22 Analysts recommend CSX to buy, 10 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the CSX stock has an average upside potential 2026 of 12.92% . Most analysts recommend the CSX stock at Purchase. |
27 Analysts have issued a sales forecast CSX 2025 . The average CSX sales estimate is $14.4b . This is 1.58% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $15.0b 6.29% , the lowest is $13.8b 2.24% .
This results in the following potential growth metrics:
2024 | $14.5b | 0.80% |
---|---|---|
2025 | $14.4b | 1.11% |
2026 | $15.0b | 4.58% |
2027 | $15.6b | 3.88% |
2028 | $16.4b | 5.16% |
2029 | $17.2b | 4.78% |
2030 | $17.4b | 1.34% |
26 Analysts have issued an CSX EBITDA forecast 2025. The average CSX EBITDA estimate is $6.6b . This is 2.59% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $7.1b 9.08% , the lowest is $6.1b 5.08% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $7.0b | 1.02% |
---|---|---|
2025 | $6.6b | 5.11% |
2026 | $7.2b | 8.64% |
2027 | $7.6b | 5.67% |
2028 | $8.2b | 8.14% |
2029 | $8.6b | 4.50% |
2024 | 48.14% | 0.22% |
---|---|---|
2025 | 46.19% | 4.06% |
2026 | 47.99% | 3.90% |
2027 | 48.81% | 1.71% |
2028 | 50.20% | 2.85% |
2029 | 50.06% | 0.28% |
29 CSX Analysts have issued a net profit forecast 2025. The average CSX net profit estimate is $3.1b . This is 0.31% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $3.4b 10.43% , the lowest is $2.8b 8.71% .
This results in the following potential growth metrics and future Net Margins:
2024 | $3.5b | 5.40% |
---|---|---|
2025 | $3.1b | 10.33% |
2026 | $3.6b | 16.67% |
2027 | $4.0b | 10.24% |
2028 | $4.4b | 11.19% |
2029 | $4.9b | 11.00% |
2030 | $5.3b | 8.26% |
2024 | 23.87% | 4.64% |
---|---|---|
2025 | 21.64% | 9.32% |
2026 | 24.14% | 11.55% |
2027 | 25.62% | 6.13% |
2028 | 27.09% | 5.74% |
2029 | 28.70% | 5.94% |
2030 | 30.66% | 6.83% |
29 Analysts have issued a CSX forecast for earnings per share. The average CSX EPS is $1.67 . This is 1.21% higher than earnings per share in the financial year 2024. The highest EPS forecast is $1.84 11.52% , the lowest is $1.52 7.88% .
This results in the following potential growth metrics and future valuations:
2024 | $1.79 | 1.65% |
---|---|---|
2025 | $1.67 | 6.70% |
2026 | $1.95 | 16.77% |
2027 | $2.15 | 10.26% |
2028 | $2.39 | 11.16% |
2029 | $2.65 | 10.88% |
2030 | $2.87 | 8.30% |
Current | 21.35 | 14.92% |
---|---|---|
2025 | 21.23 | 1.13% |
2026 | 18.19 | 14.32% |
2027 | 16.50 | 9.29% |
2028 | 14.84 | 10.06% |
2029 | 13.37 | 9.91% |
2030 | 12.35 | 7.63% |
Based on analysts' sales estimates for 2025, the CSX stock is valued at an EV/Sales of 5.90 and an P/S ratio of 4.59 .
This results in the following potential growth metrics and future valuations:
Current | 5.97 | 5.11% |
---|---|---|
2025 | 5.90 | 1.52% |
2026 | 5.64 | 4.38% |
2027 | 5.43 | 3.74% |
2028 | 5.16 | 4.91% |
2029 | 4.93 | 4.57% |
2030 | 4.86 | 1.32% |
Current | 4.64 | 3.01% |
---|---|---|
2025 | 4.59 | 1.56% |
2026 | 4.39 | 4.38% |
2027 | 4.23 | 3.74% |
2028 | 4.02 | 4.91% |
2029 | 3.84 | 4.57% |
2030 | 3.79 | 1.32% |
Analyst | Rating | Action | Date |
---|---|---|---|
Baird |
Outperform
➜
Outperform
|
Unchanged | Jul 25 2025 |
Barclays |
Overweight
➜
Overweight
|
Unchanged | Jul 24 2025 |
Benchmark |
Buy
➜
Buy
|
Unchanged | Jul 24 2025 |
JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Jul 24 2025 |
BMO Capital |
Outperform
➜
Outperform
|
Unchanged | Jul 24 2025 |
Wells Fargo |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Jul 24 2025 |
TD Cowen |
Hold
➜
Buy
|
Upgrade | Jul 21 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Baird:
Outperform
➜
Outperform
|
Jul 25 2025 |
Unchanged
Barclays:
Overweight
➜
Overweight
|
Jul 24 2025 |
Unchanged
Benchmark:
Buy
➜
Buy
|
Jul 24 2025 |
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Jul 24 2025 |
Unchanged
BMO Capital:
Outperform
➜
Outperform
|
Jul 24 2025 |
Unchanged
Wells Fargo:
Equal-Weight
➜
Equal-Weight
|
Jul 24 2025 |
Upgrade
TD Cowen:
Hold
➜
Buy
|
Jul 21 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.